pharma · Neurogenic Orthostatic Hypotension
HAC Pharma
H.A.C. Pharma
H.A.C. Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include Neurogenic Orthostatic Hypotension. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s
Company details
- Status
- Public
- HQ
- Caen, FR
- Founded
- 2007
- Employees
- 51
- Programs
- 1
- Drugs
- 2
- Patents
- 0
HAC2018-001
Approved · small molecule · Neurogenic Orthostatic Hypotension
HAC2018-001 for Neurogenic Orthostatic Hypotension is a Approved program (small_molecule) at H.A.C. Pharma with 1 ClinicalTrials.gov record(s).
Internal code HAC2018-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- H.A.C. Pharma
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Neurogenic Orthostatic Hypotension
- Status
- active
- Trials
- 1